These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 4066222)
1. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine. Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of cyclohexylamine and lysine salt of mafosfamide. Abele R; Aapro MS; Haefliger JM; Alberto P Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115 [TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498 [TBL] [Abstract][Full Text] [Related]
4. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma. Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517 [TBL] [Abstract][Full Text] [Related]
6. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Davidoff AN; Mendelow BV Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599 [TBL] [Abstract][Full Text] [Related]
8. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug. Skórski T; Kawalec M Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151 [TBL] [Abstract][Full Text] [Related]
9. Oxazaphosphorine effects in L 5222 rat leukemia. Pohl J; Reissmann T; Voegeli R Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788 [TBL] [Abstract][Full Text] [Related]
10. Design of new oxazaphosphorine anticancer drugs. Liang J; Huang M; Duan W; Yu XQ; Zhou S Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192 [TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Alberts DS; Einspahr JG; Struck R; Bignami G; Young L; Surwit EA; Salmon SE Invest New Drugs; 1984; 2(2):141-8. PubMed ID: 6469507 [TBL] [Abstract][Full Text] [Related]
12. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide. Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506 [TBL] [Abstract][Full Text] [Related]
13. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide. Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404 [TBL] [Abstract][Full Text] [Related]
14. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738 [TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro. Kovach JS; Svingen PA Invest New Drugs; 1984; 2(2):155-9. PubMed ID: 6469509 [TBL] [Abstract][Full Text] [Related]
17. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors. Atassi G; Hilgard P; Pohl J Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511 [TBL] [Abstract][Full Text] [Related]
18. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213). Deconinck E; Tamayo E; Hervé P Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586 [TBL] [Abstract][Full Text] [Related]
20. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Goldstein M; Roos WP; Kaina B Toxicol Appl Pharmacol; 2008 May; 229(1):20-32. PubMed ID: 18289623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]